sq-29548 and tartaric-acid

sq-29548 has been researched along with tartaric-acid* in 1 studies

Other Studies

1 other study(ies) available for sq-29548 and tartaric-acid

Article	Year
The stable analog carbocyclic TXA2 but not platelet-released TXA2 induces osteoclast-like cell formation. Prostaglandins, leukotrienes, and essential fatty acids, 2003, Volume: 68, Issue:4 Thromboxan A(2) (TXA(2)) is the main product of arachidonic acid metabolism in activated platelets. Platelet-released supernatants (PRS) can induce osteoclast-like cell formation in murine bone marrow cultures via a cyclooxygenase (COX)/receptor activator of NF-kB-ligand (RANKL)-dependent pathway. Here we investigated a possible linkage between platelet-released TXA(2) and osteoclastogenesis. The stable analog of TXA(2), carbocyclic TXA(2) (CTXA(2)) can induce the formation of tartrate-resistant acid phosphatase positive multinucleated cells in murine bone marrow cultures via a RANKL-dependent pathway and requires the presence of stromal cells. Interestingly, the platelet-released instable TXA(2) does not account for osteoclastogenic effects as: (a) PRS-induced osteoclastogenesis in the presence of the TXA(2) receptor antagonist SQ29548; (b) inhibition of platelet TXA(2) synthesis by indomethacin and acetylsalicylic acid failed to decrease the osteoclastogenic potential of the corresponding supernatants; and (c) CTXA(2)-induced osteoclast-like cell formation independent of indomethacin and the selective COX-2 inhibitor NS398. Topics: Acid Phosphatase; Animals; Arachidonic Acid; Aspirin; Blood Platelets; Bone Marrow Cells; Bridged Bicyclo Compounds, Heterocyclic; Carrier Proteins; Cell Nucleus; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Fatty Acids, Unsaturated; Hydrazines; Indomethacin; Membrane Glycoproteins; Mice; Nitrobenzenes; Osteoclasts; Prostaglandin-Endoperoxide Synthases; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Stromal Cells; Sulfonamides; Tartrates; Thromboxane A2	2003

Article

Year

The stable analog carbocyclic TXA2 but not platelet-released TXA2 induces osteoclast-like cell formation.

Prostaglandins, leukotrienes, and essential fatty acids, 2003, Volume: 68, Issue:4

Thromboxan A(2) (TXA(2)) is the main product of arachidonic acid metabolism in activated platelets. Platelet-released supernatants (PRS) can induce osteoclast-like cell formation in murine bone marrow cultures via a cyclooxygenase (COX)/receptor activator of NF-kB-ligand (RANKL)-dependent pathway. Here we investigated a possible linkage between platelet-released TXA(2) and osteoclastogenesis. The stable analog of TXA(2), carbocyclic TXA(2) (CTXA(2)) can induce the formation of tartrate-resistant acid phosphatase positive multinucleated cells in murine bone marrow cultures via a RANKL-dependent pathway and requires the presence of stromal cells. Interestingly, the platelet-released instable TXA(2) does not account for osteoclastogenic effects as: (a) PRS-induced osteoclastogenesis in the presence of the TXA(2) receptor antagonist SQ29548; (b) inhibition of platelet TXA(2) synthesis by indomethacin and acetylsalicylic acid failed to decrease the osteoclastogenic potential of the corresponding supernatants; and (c) CTXA(2)-induced osteoclast-like cell formation independent of indomethacin and the selective COX-2 inhibitor NS398.

Topics: Acid Phosphatase; Animals; Arachidonic Acid; Aspirin; Blood Platelets; Bone Marrow Cells; Bridged Bicyclo Compounds, Heterocyclic; Carrier Proteins; Cell Nucleus; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Fatty Acids, Unsaturated; Hydrazines; Indomethacin; Membrane Glycoproteins; Mice; Nitrobenzenes; Osteoclasts; Prostaglandin-Endoperoxide Synthases; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Stromal Cells; Sulfonamides; Tartrates; Thromboxane A2

2003